R&D at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s R&D?
- Inhibrx Biosciences, Inc. (INBX) reported R&D of $25.22M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s R&D changed year-over-year?
- Inhibrx Biosciences, Inc.'s R&D decreased by 31.6% year-over-year, from $36.88M to $25.22M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s R&D?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s R&D has grown at a -23.2% compound annual growth rate (CAGR), from $191.64M to $113.03M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.